sclc1500_S38.txt
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- MYC_TARGETS_V1+0.480
- INTERFERON_ALPHA_RESPONSE+0.430
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.360
- DNA_REPAIR+0.330
- MTORC1_SIGNALING+0.240
- OXIDATIVE_PHOSPHORYLATION+0.230
- INTERFERON_GAMMA_RESPONSE+0.220
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.310
- BILE_ACID_METABOLISM-0.250
- KRAS_SIGNALING_DN-0.220
- UV_RESPONSE_DN-0.170
- TGF_BETA_SIGNALING-0.150
- KRAS_SIGNALING_UP-0.140
- SPERMATOGENESIS-0.140
- PANCREAS_BETA_CELLS-0.130
- XENOBIOTIC_METABOLISM-0.110
- HEME_METABOLISM-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | FD76D38B-2A54-4F1A-B7C0-EF268F9D9A0E | — | — | 0.849 |
| 2 | TCGA-CV-5966-01A-11R-1686-07 | — | — | 0.848 |
| 3 | TCGA-CV-5977-01A-11R-1686-07 | — | — | 0.847 |
| 4 | B1A2365C-5491-4E85-AE7E-97B9DB8FF8D1 | — | — | 0.841 |
| 5 | TCGA-UY-A8OB-01A-12R-A42T-07 | — | — | 0.836 |
| 6 | TCGA-GV-A40E-01A-12R-A23N-07 | — | — | 0.831 |
| 7 | BS_QX12J6W1 | ATRT | — | 0.831 |
| 8 | TCGA-HD-7832-01A-11R-2132-07 | — | — | 0.830 |
| 9 | TCGA-ZF-AA4V-01A-11R-A38B-07 | — | — | 0.827 |
| 10 | DRR168607 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |